-
1 week ago | 
insights.citeline.com | Cathy Kelly
GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals? For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices. Lilly and Novo could follow the same path as insulins. (Shutterstock)
-
1 week ago | 
insights.citeline.com | Cathy Kelly
PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight. Republicans on the commission support PBM reform, but staff cuts may get in the way. (Shutterstock)
-
2 weeks ago | 
insights.citeline.com | Cathy Kelly
MAHA Commission Outlines Enhanced Research On Drug Safety In ChildrenResearch would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs. The MAHA Commission report will be followed by policy implementation strategies in August. (Shutterstock)
-
2 weeks ago | 
insights.citeline.com | Cathy Kelly
US FDA Will Help States Apply To Import Cheaper Drugs From Canada The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable. The Trump Administration wants to revive state interest in drug importation. (Shutterstock)
-
2 weeks ago | 
insights.citeline.com | Cathy Kelly
HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing HHS released the parameters for the MFN policy, which would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors. OECD countries would serve as references for lowering US prices. (Shutterstock)
-
3 weeks ago | 
insights.citeline.com | Cathy Kelly
Will International Prices Influence Medicare Price Negotiation? A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration. Stakeholders worry Medicare value assessments will adopt foreign HTA conclusions. (Shutterstock)
-
3 weeks ago | 
insights.citeline.com | Cathy Kelly
Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference. The Trump executive order has confused and concerned stakeholders. (Screenshot of White House Video)
-
3 weeks ago | 
insights.citeline.com | Cathy Kelly
Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’ Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference. The Trump executive order has confused and concerned stakeholders. (Screenshot of White House Video)
-
4 weeks ago | 
insights.citeline.com | Cathy Kelly
Medicare Negotiation Does Not Violate Due Process, Appeals Court Rules, Other Suits At Risk Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program. Ruling is first of several expected from the Third Circuit on the negotiation program. (Shutterstock)
-
1 month ago | 
insights.citeline.com | Cathy Kelly
Most Favored Nation Pricing Policy Floated In Medicaid, Coming Back To Medicare? President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention. The Most Favored Nation policy has not been considered in Medicaid before. (Shutterstock)
